Liquidia (LQDA) | News Based Sentiment Analysis

• On August 12, 2025, Liquidia reported Q2 2025 earnings of $0.49 per share, missing the expected $0.43, despite a significant 141.5% year-over-year revenue increase to $8.84 million – exceeding the $3.90 million consensus. This shows strong YUTREPIA sales are driving growth, but profitability remains a challenge.
• Following the Q2 earnings report, several analysts adjusted their price targets. Raymond James increased theirs to $41.00 on August 13, 2025, issuing a “strong-buy” rating, while Wells Fargo boosted their target to $31.00 on the same day with an “overweight” rating. Jefferies initiated coverage on August 15, 2025, with a “buy” rating and a $43.00 target.
• Insider selling continued to be a prominent theme throughout August and September. Jason Adair sold 26,057 shares on August 28, 2025, totaling $725,948.02, and Rajeev Saggar sold 20,000 shares for $557,000.00. Director Paul B. Manning sold a substantial US$19 million worth of stock on September 5, 2025, adding to concerns about management’s outlook.
• Liquidia is actively preparing for key data presentations. They will present data at the CHEST 2025 annual meeting from October 19-22, 2025, showcasing new data from the ASCENT trial of LIQ861 DPI treprostinil in PH-ILD patients. This follows their presentation of data at the PHPN Symposium from September 18-20, 2025, including safety and efficacy data through Week 8.
• Analysts currently favor Liquidia, with eight “Buy” ratings and only one “Sell” rating as of September 23, 2025. The average target price stands at $36.67, implying a potential upside of 60.12% from current levels, though forecasts predict continued negative earnings of $1.51 per share for 2025 and $1.32 for 2026.
• Stock price fluctuations were observed in late September. On September 26, 2025, the stock fell 5.1% to $21.30 with a 7% increase in trading volume. Prior to this, on September 25, 2025, the stock gapped up from $21.94 to $22.48 before closing at $22.76.
• Institutional investors experienced an 8.5% loss during the week preceding September 21, 2025, despite longer-term benefits from their holdings. Institutional ownership currently represents 64.54% of Liquidia’s stock as of September 23, 2025.

The Investment Story: September continued the narrative of strong revenue growth for Liquidia, driven by YUTREPIA, but was tempered by ongoing profitability challenges and significant insider selling, creating a mixed picture for investors.

What It Means for Investors: Liquidia remains a high-risk, high-reward investment. While the positive analyst coverage and revenue growth are encouraging, the insider sales and continued negative earnings forecasts warrant caution. Investors should closely monitor the upcoming CHEST 2025 presentation and Q3 earnings release.

Looking Ahead: Investors should watch for the presentation of data at the CHEST 2025 meeting from October 19-22, 2025, and the Q3 earnings release estimated for November 12, 2025. The company’s ability to demonstrate continued YUTREPIA growth and address profitability concerns will be crucial.

The Bottom Line: Liquidia presents a speculative opportunity. The company’s success hinges on its ability to navigate legal hurdles, address concerns surrounding insider selling, and demonstrate sustained growth in a competitive market.